ArticleBlood2022

Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.

Chihiro Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.